🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07591688
Starting soon Observational

Enucleation Ratio as a Novel Predictor of Symptomatic Improvement After HoLEP

NCT07591688 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-07-01
Last updated
2026-05-19

Condition(s) studied

Benign Prostate Obstruction (BPO)

Investigational drug(s) / intervention(s)

Holmium laser enucleation of prostate (HoLEP)

Holmium laser enucleation of prostate (HoLEP): HoLEP is a widespread and minimally invasive surgical method to treat LUTS caused by BPO. En-bloc or tri-lobar technique will be performed according to the surgeon's preference during the procedure.

Study summary

The goal of this observational study is to determine whether the rate of prostate tissue removed during surgery relative to the preoperative total prostate volume (referred to as the "enucleation ratio") predicts symptomatic improvement 3 months after HoLEP. The main question it aims to answer is:

\- What is the minimum enucleation ratio required to achieve clinically important symptomatic improvement? (Symptomatic improvement is referred to as a threshold of having an International Prostate Symptom Score (IPSS) lower than 8 points, which is determined by the American Urological Association (AUA) and European Association of Urology(EAU)).

Eligibility

Sex
MALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men aged 18 years pr older who are planned to undergo HoLEP. * Participants who are willing to give informed consent. * Participants who have moderate to severe LUTS (referring to IPSS score 8 points or more). * No history of previous prostate or urethral surgery. Exclusion Criteria: * Unwillingness to provide informed consent. * Unwillingness to provide contact information or unreachability during follow-up periods. * Incidental diagnosis of a urogenital malignancy requiring primary treatment after enrollment (e.g., bladder tumor, renal cell carcinoma, testicular tumor).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ondokuz Mayis University, Faculty of Medicine, Department of Urology Samsun Turkey (Türkiye)

More Ondokuz Mayıs University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07591688 on ClinicalTrials.gov ↗ ← All trials in Turkey